drugset / Trial / NCT02389881

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

NCT02389881

Phase 1 Completed 40 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of TAK-058 in healthy non-elderly and elderly participants.

Timeline

Start
2015-02
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-058 Unknown 25 mg Oral
Subject TAK-058 Unknown 75 mg Oral
Subject TAK-058 Unknown 150 mg Oral
Subject TAK-058 Unknown 300 mg Oral

Indications

No indication recorded.